Spiro Urea Antibacterials Balancing MmpL3 Inhibition and Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for novel small compounds with antibacterial activity to effectively treat multidrug-resistant and extensively drug-resistant tuberculosis (MDR-TB and XDR-TB) due to the limitations of existing drugs in penetrating Mycobacterium tuberculosis cell walls and the rise of resistant strains.
Innovation Solution
Development of urea motif-containing compounds with a spiro structure, which act as potent inhibitors of MmpL3 and EpH, enhancing antibacterial properties and bioavailability, and are formulated into pharmaceutical compositions for various administration routes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If hydrophobic MmpL3 inhibitors are used to achieve potent antibacterial activity, then inhibitory effect is improved, but bioavailability is reduced
Solution Approach 1:
The patent modifies the chemical parameters of MmpL3 inhibitors by introducing polar groups (hydroxyl, carboxyl, amino groups) and adjusting molecular weight to reduce hydrophobicity. This changes the physicochemical properties to improve bioavailability while maintaining inhibitory activity against mycobacteria.
Solution Approach 2:
The patent creates composite molecular structures combining hydrophobic regions (for MmpL3 binding) with hydrophilic regions (for improved bioavailability). This dual-character molecular design allows the compound to penetrate the mycobacterial cell wall while being sufficiently soluble in biological fluids for effective delivery.
2Ease of operation
If existing first-line antibiotics are used to treat MDR-TB and XDR-TB, then treatment simplicity is maintained, but treatment effectiveness is reduced due to resistance
Solution Approach 1:
The patent introduces a new intermediary compound that acts through a novel mechanism of action by inhibiting MmpL3, a membrane transporter essential for mycolic acid transport. This intermediary approach bypasses the resistance mechanisms that have rendered traditional antibiotics ineffective against MDR-TB and XDR-TB strains.
Solution Approach 2:
The patent changes the therapeutic parameter by targeting a completely different biological pathway (MmpL3 inhibition) compared to traditional antibiotics. This parameter change in mechanism of action allows effective treatment of resistant strains while maintaining reasonable treatment simplicity.
3Reliability
If second-line drugs are used to treat MDR-TB, then treatment effectiveness is improved, but treatment complexity and toxicity increase due to extended administration duration
Solution Approach 1:
The patent extracts and targets the specific essential function of MmpL3 in mycobacterial cell wall biosynthesis. By focusing on this single essential pathway, the treatment achieves high effectiveness without requiring complex multi-drug regimens, thereby reducing treatment complexity while maintaining efficacy.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The invention concerns a compound comprising a residue consisting of a first molecular ring and a second molecular ring connected to each other via one common atom which compound has a structure according to formula I wherein G1 is independently selected from a group consisting of C, O, N, and S, G2 is independently selected from a group consisting of C and H, G3 is independently selected from a group consisting of C, O, N and S and G4 is independently selected from a group consisting of C=O, CH2, C=S and C=NH.